

Supplementary Table 1. Comparison of GLP-1RAs use approval criteria and prices in Korea and Japan

	Korea	Japan
Not covered by insurance	1. Administered as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in patients with the following conditions: ① Initial BMI ≥ 30 kg/m ² OR ② one or more weight-related comorbidities ^a with an initial BMI of 27 kg/m ² or more but less than 30 kg/m ² 2. Administered to reduce the risk of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in patients with confirmed cardiovascular disease and an initial BMI ≥ 27 kg/m ²	Not available
Insurance covered	Not available	1. BMI ≥ 35 kg/m ² 2. BMI ≥ 27 kg/m ² ; at least one of hypertension, dyslipidemia, type 2 diabetes mellitus; and at least two obesity-related comorbidities ^b
Drug mass	W/week	¥/week ^{c,d} (W)
0.25 mg	93,006	1,876 (17,447)
0.5 mg		3,201 (29,769)
1.0 mg		5,901 (54,879)
1.7 mg		7,903 (73,498)
2.4 mg		10,740 (99,882)

GLP-1 RA, glucagon-like peptide-1 receptor agonist.

^aDysglycemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease, ^bHypertension, dyslipidemia, type 2 diabetes mellitus, hyperuricemia, coronary artery disease, cerebral infarction, transient ischemic attack, non-alcoholic fatty liver disease, menstrual irregularities, obstructive sleep apnea syndrome, osteoarthritis, obesity-related kidney disease, ^c10%–30% self-payment depending on age and income, ^d<https://pro.novonordisk.co.jp/products/wegovy.html?profession=physician>.